Superworth

Spero Therapeutics free cash flow SPRO

Cash from operations less capital spending, by quarter and over the last twelve months, from 2016.

Last 12 months, to Sep 30, 2021
n/m
a quarter missing
Latest quarter, Q3 FY21
−$5M
Fiscal year 2020
−$86M

Spero Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY21, it was −$5M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2020−$86Mn/a
FY2019−$50.3Mn/a
FY2018n/an/a
FY2016n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q3 FY21−$5Mn/an/a
Q4 FY20−$16.4Mn/a−$86M
Q3 FY20−$21.3Mn/a−$87.1M
Q2 FY20−$24.9Mn/a−$75.5M
Q1 FY20−$23.4Mn/a−$62.7M
Q4 FY19−$17.5Mn/a−$50.3M
Q3 FY19−$9.7Mn/a−$48.8M
Q2 FY19−$12.2Mn/an/a
Q1 FY19−$11Mn/an/a
Q4 FY18−$15.9Mn/an/a
Q4 FY16−$9.5Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first, today.

CompanyFree cash flow yield
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products8.5%
ARVNArvinas−43.7%
PBYIPuma Biotechnology7.2%
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics5.6%
CRMDCorMedixn/m
Peer median7.2%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Spero Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.